Search
Pyxis Oncology Inc
PYXSAdd to Watchlist
2.630USD
-0.220-7.72%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
166.62MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-7.72%
5 Days
+17.94%
1 Month
+53.80%
6 Months
+128.70%
Year to Date
+128.70%
1 Year
+119.17%
Key Figures
2.790Open
3.000High
694.30KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.11%Turnover Ratio
2.850Prev. Close
2.630Low
1.27MTurnover
LossP/E Static
3.09P/B
0.00%Div Yield TTM
-81.67%ROA
5.55052wk High
0.39Volume Ratio
-77.33MNet Profit
62.69MShares
-1.3013EPS TTM
1.43Beta
-121.66%ROE
0.97052wk Low
12.98%Amplitude
78.37%Gross Margin
166.62MMarket Cap
9.84Reward/Risk
6.87%Risk Rate
TradingKey Stock Score of Pyxis Oncology Inc
Currency: USD Updated: 2026-07-02Key Insights
Pyxis Oncology Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 94 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pyxis Oncology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Pyxis Oncology Inc Highlights
StrengthsRisks
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Growing
The company is in a growing phase, with the latest annual income totaling USD 13.86M.
Fairly Valued
The company’s latest PE is -2.02, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.75M shares, decreasing 34.52% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 27.01K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.45.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
7.000
Target Price
+144.76%
Upside Space
Pyxis Oncology Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pyxis Oncology Inc Info
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Ticker SymbolPYXS
CompanyPyxis Oncology Inc
CEOSullivan (Lara S)
Websitehttps://pyxisoncology.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52819.700
-22.800 (-0.04%)
29610.100
+298.700 (+1.02%)
7497.800
+26.300 (+0.35%)
14941.000
+138.000 (+0.93%)
69486.000
+1338.000 (+1.96%)
6370.700
+17.900 (+0.28%)
68.543
+0.199 (+0.29%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.980
+56.070 (+1.36%)
FAQs
What is the current price of Pyxis Oncology Inc (PYXS)?
The current price of Pyxis Oncology Inc (PYXS) is 2.63.
What is the symbol of Pyxis Oncology Inc?
The ticker symbol of Pyxis Oncology Inc is PYXS.
What is the 52-week high of Pyxis Oncology Inc?
The 52-week high of Pyxis Oncology Inc is 5.55.
What is the 52-week low of Pyxis Oncology Inc?
The 52-week low of Pyxis Oncology Inc is 0.97.
What is the market capitalization of Pyxis Oncology Inc?
The market capitalization of Pyxis Oncology Inc is 164.88M.
Is Pyxis Oncology Inc (PYXS) currently rated as Buy, Hold, or Sell?
According to analysts, Pyxis Oncology Inc (PYXS) has an overall rating of Buy, with a price target of 7.00.
What is the Earnings Per Share (EPS TTM) of Pyxis Oncology Inc (PYXS)?
The Earnings Per Share (EPS TTM) of Pyxis Oncology Inc (PYXS) is -1.28.